1. Search Result
Search Result
Results for "

corpus

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

10

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12956
    Dinoprost
    2 Publications Verification

    Prostaglandin F2α; PGF2α

    Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Endocrinology
    Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .
    Dinoprost
  • HY-12956A
    Dinoprost tromethamine salt
    2 Publications Verification

    Prostaglandin F2α tromethamine salt; PGF2α THAM; Prostaglandin F2α THAM

    Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Endocrinology
    Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour .
    Dinoprost tromethamine salt
  • HY-12956S

    Prostaglandin F2a-d4; PGF2α-d4

    Isotope-Labeled Compounds Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Endocrinology
    Dinoprost-d4 is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .
    Dinoprost-d4
  • HY-126762

    Progesterone Receptor Endocrinology
    Fenprostalene is an analog of Dinoprost (PGF2α) (HY-12956) that is used in veterinary medicine to induce corpus luteum regression and blood Progesterone (HY-N0437) levels reduction in dogs. Fenprostalene is potent in ameliorating pyometra and inducing abortion .
    Fenprostalene
  • HY-19548

    Arginase Endocrinology
    BEC, an arginine analogue, is a slow-binding competitive inhibitor of the binuclear manganese metalloenzyme arginase. BEC enhances substrate flux to NO synthase, thereby enhancing NO-dependent smooth muscle relaxation in the corpus cavernosum, and enhances penile erection .
    BEC
  • HY-113909

    Prostaglandin F2α (methoxyamine); PGF2α (methoxyamine)

    Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Endocrinology
    Dinoprost methoxyamine is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost methoxyamine is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost methoxyamine plays a key role in the onset and progression of labour .
    Dinoprost (methoxyamine)
  • HY-12956R

    Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Endocrinology
    Dinoprost (Standard) is the analytical standard of Dinoprost. This product is intended for research and analytical applications. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .
    Dinoprost (Standard)
  • HY-12956S2

    Prostaglandin F2α-13C5; PGF2α-13C5

    Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Isotope-Labeled Compounds Endocrinology
    Dinoprost- 13C5 is 13C labeled Dinoprost (HY-12956). Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .
    Dinoprost-13C5
  • HY-12956AR

    Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Endocrinology
    Dinoprost (tromethamine salt) (Standard) is the analytical standard of Dinoprost (tromethamine salt). This product is intended for research and analytical applications. Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour .
    Dinoprost (tromethamine salt) (Standard)
  • HY-12956S1

    Prostaglandin F2a-d9; PGF2α-d9

    Isotope-Labeled Compounds Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Endocrinology
    Dinoprost-d9 is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .
    Dinoprost-d9
  • HY-135730

    Endogenous Metabolite Endocrinology
    Aglepristone is a synthetic steroidal antiprogestin with abortifacient activity. Aglepristone is used exclusively as an abortifacient in pregnant animals. Aglepristone has been shown to be a safe and effective abortifacient in the second trimester of pregnancy. Aglepristone causes termination of pregnancy and does not cause fetal resorption. During aglepristone treatment, an increase in plasma concentrations of prolactin was observed, while progesterone levels remained unchanged. The use of aglepristone also resulted in early arrest of corpus luteum function and a shortening of the estrus interval .
    Aglepristone
  • HY-103186
    MRS-1706
    1 Publications Verification

    Adenosine Receptor Inflammation/Immunology
    MRS-1706 is a potent and selective adenosine A2B receptor inverse agonist. MRS-1706 has Ki values of 1.39, 112, 157, and 230 nM for human A2B, A2A, A1 and A3 receptors respectively. MRS-1706 blocks adenosine-mediated cAMP induction .
    MRS-1706
  • HY-136494

    ICI 81008

    Endogenous Metabolite Endocrinology
    Fluprostenol (ICI 81008) is a synthetic prostaglandin F2α (PGF2α) derivative. Fluprostenol, as a luteolytic agent, can cause luteal degeneration and regulate reproductive cycle. Fluprostenol can be used in the study of infertility in animals and the control of the reproductive cycle of domestic animals .
    Fluprostenol
  • HY-103186R

    Adenosine Receptor Inflammation/Immunology
    MRS-1706 (Standard) is the analytical standard of MRS-1706. This product is intended for research and analytical applications. MRS-1706 is a potent and selective adenosine A2B receptor inverse agonist. MRS-1706 has Ki values of 1.39, 112, 157, and 230 nM for human A2B, A2A, A1 and A3 receptors respectively. MRS-1706 blocks adenosine-mediated cAMP induction .
    MRS-1706 (Standard)
  • HY-119409

    Phacetoperane free base

    Dopamine Transporter Neurological Disease
    Levophacetoperane (Phacetoperane free base) competitively inhibits the uptake of norepinephrin and dopamine .
    Levophacetoperane
  • HY-18252
    Avanafil
    1 Publications Verification

    TA1790

    Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite Cardiovascular Disease Endocrinology
    Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil
  • HY-18252R

    Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite Cardiovascular Disease Endocrinology
    Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil (Standard)
  • HY-18252A

    TA1790 dibenzenesulfonate

    Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite Cardiovascular Disease Endocrinology
    Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil dibenzenesulfonate
  • HY-18252S1

    Endogenous Metabolite NO Synthase Phosphodiesterase (PDE) Isotope-Labeled Compounds Cardiovascular Disease Endocrinology
    Avanafil- 13C5, 15N,d2 is 15N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil-13C5,15N,d2
  • HY-A0066A

    Imidaline hydrochloride; NSC35110 hydrochloride

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Tolazoline hydrochloride (Imidaline hydrochloride) is an α-adrenergic receptor antagonist. Tolazoline hydrochloride inhibits Noradrenaline (HY-13715)-induced cell contraction, modulates vascular resistance, increases arterial pressure, and reverses bradycardia and tachypnea. Tolazoline hydrochloride can be used to study erectile dysfunction, α2-adrenergic receptor agonist-related poisoning, and skin vascular disease research .
    Tolazoline hydrochloride
  • HY-A0066AR

    Imidaline hydrochloride (Standard); NSC35110 hydrochloride (Standard)

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Tolazoline (hydrochloride) (Standard) is the analytical standard of Tolazoline hydrochloride (HY-A0066A). This product is intended for research and analytical applications. Tolazoline hydrochloride (Imidaline hydrochloride) is an α-adrenergic receptor antagonist. Tolazoline hydrochloride inhibits Noradrenaline (HY-13715)-induced cell contraction, modulates vascular resistance, increases arterial pressure, and reverses bradycardia and tachypnea. Tolazoline hydrochloride can be used to study erectile dysfunction, α2-adrenergic receptor agonist-related poisoning, and skin vascular disease research .
    Tolazoline hydrochloride (Standard)
  • HY-N7690

    Calcium Channel Cardiovascular Disease Metabolic Disease
    3,5,7,3’,4’-Pentamethoxyflavone is a Ca 2+ channel inhibitor. 3,5,7,3’,4’-Pentamethoxyflavone can protect DNA from oxidative damage. 3,5,7,3’,4’-Pentamethoxyflavone can induce relaxation of the human corpus cavernosum through calcium mobilization-related mechanisms. 3,5,7,3’,4’-Pentamethoxyflavone can promote the expression of eNOS and cystathionine gamma lyase CSE proteins in middle-aged male rats and regulate vascular function. 3,5,7,3’,4’-Pentamethoxyflavone can be used in research related to diabetes and cardiovascular diseases .
    3,5,7,3′,4′-Pentamethoxyflavone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: